Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

PASCOE-Agil HOM-Injektopas in the Treatment of Rheumatic Disorders (157)

This study has been completed.
Information provided by:
Pascoe Pharmazeutische Praeparate GmbH Identifier:
First received: June 16, 2009
Last updated: May 10, 2010
Last verified: May 2010

The purpose of this observational study is to give an overview of the use of PASCOE-Agil HOM-Injektopas in a 2-4 week treatment of rheumatic disorders of different aetiology and localisation, displaying a variety of symptoms.

Efficacy and tolerability of the drug will be assessed. Special regard will be taken to the administration management in relation to the Summary of Product Characteristics (SmPC).

Rheumatic Disorders

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: PASCOE-Agil HOM-Injektopas in the Treatment of Rheumatic Disorders: A Non-interventional Observational Study.

Further study details as provided by Pascoe Pharmazeutische Praeparate GmbH:

Primary Outcome Measures:
  • Efficacy of the drug, measured by decrease in disease-related symptoms, (Visual Analog Scale (VAS)) [ Time Frame: Beginning, 2 + 4 weeks ] [ Designated as safety issue: No ]
  • Tolerability of the drug, measured by documentation of adverse drug reactions (ADR) [ Time Frame: from enrollment until completion ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Acceptance of the drug by medical personnel and patients [ Time Frame: from enrollment until completion ] [ Designated as safety issue: Yes ]

Enrollment: 1389
Study Start Date: January 2009
Study Completion Date: May 2009
Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)
Observational group
Patients suffering from rheumatic disorders of different types and origins, especially those with arthralgia, myalgia, lumbago, or other diagnoses.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Cohort of adult patients suffering from rheumatic diseases and relating symptoms who present themselves in German Primary Care Centers.


Due to the design as an Observational Study no inclusion or exclusion criteria are named. The included patient group is described under "Cohort / Group".

Observational Criteria:

  • Males and females
  • At least 18 years old
  • Rheumatic disease with accompanying symptoms, e.g. arthralgia, myalgia, lumbago etc.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00922428

Sponsors and Collaborators
Pascoe Pharmazeutische Praeparate GmbH
Study Director: Anja Braschoss, MD Pascoe Pharmazeutische Praeparate GmbH
  More Information

No publications provided

Responsible Party: Anja Braschoss, MD, Pascoe pharmazeutische Praeparate GmbH, Clinical Research Identifier: NCT00922428     History of Changes
Other Study ID Numbers: 157 A 07 PA
Study First Received: June 16, 2009
Last Updated: May 10, 2010
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Pascoe Pharmazeutische Praeparate GmbH:
PASCOE-Agil HOM Injektopas

Additional relevant MeSH terms:
Rheumatic Diseases
Connective Tissue Diseases
Joint Diseases
Muscular Diseases
Musculoskeletal Diseases
Musculoskeletal Pain
Nervous System Diseases
Neurologic Manifestations
Neuromuscular Diseases
Pathologic Processes
Signs and Symptoms processed this record on November 25, 2014